Summary:
In order to analyze the outcome of patients with chronic myeloid leukemia (CML) who relapse after allogeneic stem cell transplantation (SCT), we investigated data from 107 patients reported to the Spanish Registry, GETH. In all, 93 (87%) patients were treated after relapse; 36 out of 49 that failed to achieve a response received a second relapse-treatment, and seven a third one. At the last follow-up, the number of patients in molecular or cytogenetic remission was 29 and 13, respectively. Overall survival and progression-free survival after relapse were 53.6% (95% CI: 42.9–64.2) and 52% (95% CI: 41–63) at 5 years, respectively. In multivariate analysis, survival was significantly related to CML phase at relapse (cytogenetic or chronic phase vs advanced phases) and time from transplant to relapse (<1 vs ⩾1 year). Patients with no adverse factors had a better survival compared with patients with one or two adverse features (65 vs 35 vs 0%, respectively). We conclude that a significant proportion of CML patients that relapse after transplantation can regain complete and long-lasting remissions with one or more salvage therapies. Disease stage at relapse and time from transplant to relapse should be taken into account when comparing results of different salvage treatments.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Goldman JM, Apperley JF, Jones L et al. Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med 1986; 14: 202–207.
Thomas ED, Clift RA, Fefer A et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986; 104: 155–163.
van Rhee F, Szydlo RM, Hermans J et al. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1997; 20: 553–560.
Devergie A, Reiffers J, Vernant JP et al. Long-term follow-up after bone marrow transplantation for chronic myelogenous leukemia: factors associated with relapse. Bone Marrow Transplant 1990; 5: 379.
Martin PJ, Clift RA, Fisher LD et al. HLA-identical marrow transplantation during accelerate phase chronic myelogenous leukemia: analysis of survival and remission duration. Blood 1988; 72: 1978.
Goldman JM, Gale RP, Horowitz MM et al. Bone marrow transplantation for the treatment of chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988; 108: 806–814.
Higano CS, Chielens D, Raskind W et al. Use of alpha-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation. Blood 1997; 82: 3211–3219.
Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462–2465.
Cullis JO, Jiang YZ, Scwarer AP et al. Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood 1992; 79: 1379–1381.
Dazzi F, Szydlo RM, Cross N et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2000; 96: 2712–2716.
Guglielmi C, Arcese W, Dazzi F et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 2002; 100: 397–405.
Arcese W, Goldman JM, D’Arcangelo E et al. Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Chronic Myeloid Leukemia Working Party. European Bone Marrow Transplantation Group. Blood 1993; 82: 3211–3219.
Olavarria E, Ottmann OG, Deininger M et al. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 2003; 17: 1707–1712.
Kantarjian HM, O’Brien S, Cortes JE et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002; 100: 1590–1595.
Guglielmi C, Arcese W, Hermans J et al. Risk assessment in patients with Ph+ chronic myelogenous leukemia at first relapse after allogeneic stem cell transplant: an EBMT retrospective analysis. Blood 2000; 95: 3328–3334.
Gratwohl A, Hermans J, Goldman JM et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet 1998; 352: 1087–1092.
Hughes TP, Morgan GJ, Martiat P, Goldman JM . Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. Blood 1991; 77: 874–878.
Hochhaus A, Weisser A, La Rosee P et al. Detection and quantification of residual disease in chronic myelogenous leukemia. Leukemia 2000; 14: 998–1005.
Olavarria E, Kanfer E, Szydlo R et al. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2001; 97: 1560–1565.
Arcese W, Mauro FR, Alimema G et al. Interferon therapy for Ph1-positive CML patients relapsing after T-cell depleted allogeneic bone marrow transplantation. Bone Marrow Transplant 1990; 5: 309–315.
Steegman JL, Casado LF, Tomas JF et al. Interferon alpha for chronic myeloid leukemia relapsing after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 23: 483–488.
Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031–1037.
Kantarjian H, Sawyers C, Hochhaus A, et al, The International STI571 CML Study Group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645–652.
Cervantes F on behalf of the IRIS Study Group. Durability of responses to imatinib in newly diagnosed chronic-phase chronic myeloid leukemia (CML): 24-month-update from the IRIS study. Blood 2003; 102 (Suppl. 1): 181a.
Mattei D, Saglio G, Gottardi E et al. Persisting molecular remission ten years after donor lymphocyte infusion for hematologic relapse in chronic myeloid leukemia. Haematologica 2001; 86: 545–546.
Raiola AM, Van Lint MT, Valbonesi M et al. Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions. Bone Marrow Transplant 2003; 31: 687–693.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Martínez, C., Gomez, V., Tomás, J. et al. Relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: outcome and prognostic factors. The Chronic Myeloid Leukemia Subcommittee of the GETH (Grupo Español de Trasplante Hemopoyético). Bone Marrow Transplant 36, 301–306 (2005). https://doi.org/10.1038/sj.bmt.1705063
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705063